Featured Research

from universities, journals, and other organizations

Forteo's Bone-building Power Shown In Arthritis Patients

Date:
November 26, 2007
Source:
University of Alabama at Birmingham
Summary:
In a head-to-head comparison of the two drugs, Forteo increased lumbar spine density measurements by 7.2 percent compared to 3.4 percent for Fosamax, and it boosted hip density measurements by 3.8 percent compared to 2.4 percent for Fosamax. The study looked at changes in bone density over the course of 18 months in arthritis patients with prednisone-induced osteoporosis.

he osteoporosis drug Forteo works better than Fosamax to strengthen bones in arthritis patients with prednisone-induced osteoporosis, according to a new study from a researcher at the University of Alabama at Birmingham (UAB.)

In a head-to-head comparison of the two drugs, Forteo, part of a class of drugs called parathyroid hormones, more than doubled osteoporosis patients' bone density measurements and significantly reduced the risk of new spinal fractures when compared to those taking Fosamax.

Forteo increased lumbar spine density measurements by 7.2 percent compared to 3.4 percent for Fosamax, and it boosted hip density measurements by 3.8 percent compared to 2.4 percent for Fosamax, the UAB researcher said. The study looked at changes in bone density over the course of 18 months.

The findings are published in the Nov. 15 issue of the New England Journal of Medicine.

"Patients and their doctors need more bone-building options," said Kenneth Saag, M.D., M.Sc., a professor in the UAB Division of Clinical Immunology and Rheumatology and the study's lead author.

"Because having arthritis and being on medication for that disease is important. Reducing your risk of hip fracture or spinal compression is equally important," Saag said.

"This study significantly improves our understanding of treatment options for secondary osteoporosis, which is osteoporosis caused by taking glucocorticoid drugs like prednisone," he said.

Glucocorticoids like prednisone are widely used by arthritis patients and others to help reduce inflammation and shrink swollen tissues and joints. But these drugs can cause another problem -- an increased risk of bone loss, bone fracture and osteoporosis.

International guidelines currently recommend a class of drugs called bisphosphonates, which includes Fosamax, for patients diagnosed with and at risk for glucocorticoid-induced osteoporosis. Saag said many experts hope Forteo is part of the next wave of medicines that work to build back bone, reduce bone loss and minimize fracture risks in arthritis patients.

For the NEJM study, 428 adults with glucocorticoid-induced osteoporosis were chosen to receive either a once-daily Forteo injection or a once-daily Fosamax pill. Their spine and hip bone density measurements were taken at the start of the trial and at the end using a DEXA scan, a low-level X-ray machine that detects slight changes in bone density.

In addition to taking bone-density measurements, the study authors found the Forteo patients had higher levels of protein and biological markers of bone formation in their urine when compared to the Fosamax group.

The differences between Forteo and Fosamax in terms of serious side effects were not significant, Saag said. He and the study's co-authors conclude that because parathyroid hormone appears to trigger the growth of bone-forming cells called osteoblasts, Forteo may effectively counteract the negative effects of glucocorticoid use in bones. Fosamax works to counteract osteoporosis through a different cell pathway.

Currently Forteo is only approved for use in postmenopausal women with osteoporosis, and in certain cases for men with hormonal-linked osteoporosis. The drug maker Eli Lilly and Company is awaiting federal approval to have Forteo listed among approved medicines in patients with glucocorticoid-induced osteoporosis.


Story Source:

The above story is based on materials provided by University of Alabama at Birmingham. Note: Materials may be edited for content and length.


Cite This Page:

University of Alabama at Birmingham. "Forteo's Bone-building Power Shown In Arthritis Patients." ScienceDaily. ScienceDaily, 26 November 2007. <www.sciencedaily.com/releases/2007/11/071114183257.htm>.
University of Alabama at Birmingham. (2007, November 26). Forteo's Bone-building Power Shown In Arthritis Patients. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2007/11/071114183257.htm
University of Alabama at Birmingham. "Forteo's Bone-building Power Shown In Arthritis Patients." ScienceDaily. www.sciencedaily.com/releases/2007/11/071114183257.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins